Pfizer Inc.’s decision late last week to shelve the twice-daily form of its oral GLP-1 danuglipron means the US giant has slipped down the rankings of companies trying to bring oral forms of incretin drugs – the wildly successful therapies for diabetes and obesity – to market.
Time For Oral Incretins To Prove Their Worth
Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.
